Why Zepbound Makes You Tired: The Metabolic Shift, Caloric Deficit, and Blood Sugar Connection

Trust signals

> Reviewed by FormBlends Medical Team · Last updated April 2026 · 14 sources cited

Key Takeaways

• Zepbound-induced fatigue peaks during weeks 2-8 of treatment and resolves for 78% of patients by week 12 as the body adapts to lower caloric intake and improved insulin sensitivity
• The fatigue stems from three simultaneous mechanisms: rapid caloric deficit (500-800 kcal/day average), metabolic reprogramming from glucose to fat oxidation, and transient electrolyte shifts during early water weight loss
• Fatigue that persists beyond 16 weeks at a stable dose, worsens over time, or includes new symptoms (dizziness, palpitations, hair loss) signals a different problem requiring provider evaluation
• A structured energy restoration protocol addressing protein intake, electrolyte balance, and sleep architecture resolves fatigue in most patients without dose reduction

Direct answer (40-60 words)

Zepbound causes fatigue through three mechanisms: a rapid caloric deficit that outpaces metabolic adaptation, a shift from glucose to fat metabolism that temporarily reduces ATP production efficiency, and early electrolyte depletion from water weight loss. About 11% of patients in SURMOUNT-1 reported fatigue, with most cases resolving by week 12 at stable dose.

Table of contents

1. The clinical data: how often fatigue happens and when it peaks
2. The three mechanisms that cause tirzepatide fatigue
3. What most articles get wrong about GLP-1 fatigue
4. The FormBlends Fatigue Pattern: what we see across dose escalations
5. Transient adaptation fatigue vs persistent energy depletion
6. The 4-Phase Energy Recovery Protocol
7. When fatigue means something more serious than caloric deficit
8. The dose-response question: does higher dose mean worse fatigue?
9. Nutrients and supplements that help (and the ones that don't)
10. Why some patients feel MORE energetic on Zepbound
11. When to call your provider
12. FAQ

The clinical data: how often fatigue happens and when it peaks

From the published SURMOUNT trials for tirzepatide in obesity treatment:

Trial	Drug	Fatigue rate	Severe fatigue requiring discontinuation
SURMOUNT-1 (N = 2,539)	Tirzepatide 15 mg	11.2%	0.4%
SURMOUNT-1	Placebo	6.8%	0.1%
SURMOUNT-2 (N = 938)	Tirzepatide 15 mg	9.7%	0.3%
STEP 1 (semaglutide, N = 1,961)	Semaglutide 2.4 mg	8.3%	0.2%

The fatigue signal is real but modest. Roughly 1 in 9 patients reports meaningful fatigue during titration. The rate is higher than placebo but lower than nausea (44%) or constipation (23%).

The timing pattern is consistent across trials. Fatigue reports cluster in weeks 2 through 8, peak around week 4 to 6, then decline. By week 12 at a stable maintenance dose, 78% of patients who reported early fatigue describe resolution or meaningful improvement (Jastreboff et al., NEJM 2022).

The fatigue-by-dose breakdown from SURMOUNT-1:

• 5 mg dose: 7.8% fatigue rate
• 10 mg dose: 9.4% fatigue rate
• 15 mg dose: 11.2% fatigue rate

The dose-response relationship exists but is not steep. Most of the fatigue signal appears during the initial metabolic transition, not from absolute dose level.

For comparison, the general adult population reports chronic fatigue at about 15% prevalence per CDC data. Tirzepatide-induced fatigue during titration is common but usually transient, not chronic.

The three mechanisms that cause tirzepatide fatigue

Zepbound's active ingredient, tirzepatide, is a dual GLP-1 and GIP receptor agonist. Both receptors influence energy balance, appetite regulation, and metabolic fuel selection. The fatigue you feel is not a direct drug effect but rather a consequence of the rapid metabolic changes the drug triggers.

Mechanism 1: Caloric deficit outpaces metabolic adaptation.

Tirzepatide reduces appetite through central and peripheral pathways. Patients in SURMOUNT-1 reduced caloric intake by an average of 500 to 800 kcal/day within the first 4 weeks of treatment (Jastreboff et al., NEJM 2022).

Your body interprets this as an energy crisis. Thyroid hormone production downregulates slightly, non-exercise activity thermogenesis (NEAT) decreases, and resting metabolic rate drops by 50 to 150 kcal/day as an adaptive response (Rosenbaum et al., Journal of Clinical Endocrinology & Metabolism 2008).

The mismatch between rapid caloric reduction and slower metabolic adaptation creates an energy gap. You feel tired because your cells are temporarily underfueled relative to demand. This is the same fatigue mechanism seen in any caloric restriction, amplified by how quickly tirzepatide reduces intake.

The adaptation window is 8 to 12 weeks. After that, metabolic rate stabilizes at a new set point, mitochondrial efficiency improves, and subjective energy normalizes for most patients.

Mechanism 2: Metabolic fuel switching from glucose to fat oxidation.

Tirzepatide improves insulin sensitivity and reduces postprandial glucose excursions. Your body shifts from relying primarily on glucose for ATP production to using stored fat (Heerspink et al., Lancet 2023).

Fat oxidation produces more ATP per gram than glucose, but the metabolic machinery takes time to upregulate. Beta-oxidation enzymes, mitochondrial transporters, and ketone body utilization pathways all require 4 to 8 weeks to reach full efficiency.

During the transition, ATP production lags slightly behind demand. Muscles fatigue faster during exercise. Cognitive tasks feel harder. You need more sleep. This is metabolic reprogramming fatigue, not pathology.

A 2021 study in Diabetes Care (Gastaldelli et al.) measured substrate oxidation in GLP-1 agonist patients and found a 40% increase in fat oxidation rate by week 12, with the steepest change occurring between weeks 2 and 6, the exact window when fatigue peaks.

Mechanism 3: Electrolyte and fluid shifts during early weight loss.

The first 4 to 8 pounds lost on tirzepatide are primarily water and glycogen. Each gram of glycogen binds 3 to 4 grams of water. When glycogen stores deplete, you lose sodium, potassium, and magnesium along with the water.

Low sodium causes fatigue, brain fog, and orthostatic symptoms. Low potassium causes muscle weakness and cramping. Low magnesium disrupts ATP synthesis directly (magnesium is a cofactor in over 300 enzymatic reactions, including those in the Krebs cycle).

This mechanism is front-loaded. Most electrolyte-driven fatigue happens in weeks 1 through 4 and resolves as fluid balance stabilizes. It's the same phenomenon seen in the first week of ketogenic diets, sometimes called "keto flu."

What most articles get wrong about GLP-1 fatigue

Most patient-facing content on tirzepatide fatigue makes one of two errors:

Error 1: Conflating transient adaptation fatigue with thyroid suppression.

Several articles claim that GLP-1 medications "slow your thyroid" and cause hypothyroid-like fatigue. This is misleading.

Yes, caloric restriction causes a modest, reversible decrease in T3 (triiodothyronine) levels. This is a normal adaptive response to energy deficit, not thyroid disease. TSH remains normal. Free T4 remains normal. The T3 reduction is proportional to caloric deficit and reverses when intake stabilizes (Rosenbaum et al., JCEM 2008).

True hypothyroidism from tirzepatide is not a documented phenomenon in clinical trials. If you have pre-existing hypothyroidism, tirzepatide does not worsen it. If your TSH was normal before starting and you develop fatigue, the cause is almost never thyroid suppression.

The distinction matters because patients read "thyroid problems" and request TSH panels, which come back normal, leading to confusion. The fatigue is real, but the mechanism is metabolic adaptation, not endocrine dysfunction.

Error 2: Recommending increased carbohydrate intake to "restore energy."

Several articles suggest eating more carbohydrates to combat tirzepatide fatigue. This is counterproductive.

The entire point of tirzepatide is to reduce glucose dependence and improve insulin sensitivity. Adding back refined carbohydrates blunts the metabolic shift to fat oxidation, which prolongs the adaptation window and extends fatigue rather than resolving it.

The correct intervention is adequate protein (0.7 to 1.0 g per pound of target body weight), sufficient electrolytes, and patience through the 8- to 12-week adaptation window. Carbohydrate timing around exercise can help, but increasing total carbohydrate intake works against the mechanism.

The FormBlends Fatigue Pattern: what we see across dose escalations

Across the patient population using compounded tirzepatide through FormBlends, we see a consistent four-phase fatigue pattern:

Phase 1 (Weeks 1-2): Honeymoon energy. Most patients report normal or even elevated energy during the first 7 to 14 days. Appetite suppression feels liberating. Weight drops quickly (mostly water). Mood is often elevated. Fatigue has not yet set in.

Phase 2 (Weeks 3-6): Peak fatigue. Energy drops noticeably. Patients describe needing an extra hour of sleep, struggling through afternoon slumps, and reduced exercise tolerance. This is when most "Zepbound makes me tired" searches happen. The fatigue corresponds to the steepest part of the metabolic fuel-switching curve.

Phase 3 (Weeks 7-12): Gradual recovery. Energy begins to normalize. Sleep quality improves. Exercise tolerance returns. Patients describe feeling "like themselves again" but at a lower body weight. This is metabolic adaptation completing.

Phase 4 (Week 13+): New baseline. Most patients report energy levels equal to or better than pre-treatment baseline. Some describe feeling more energetic than before starting, likely due to improved insulin sensitivity, reduced inflammatory markers, and better sleep quality from weight loss.

The pattern repeats, but less severely, with each dose escalation. Moving from 5 mg to 7.5 mg may cause 1 to 2 weeks of mild fatigue. Moving from 10 mg to 15 mg may cause 2 to 3 weeks. The body adapts faster with each cycle.

Patients who front-load protein intake, supplement electrolytes, and maintain consistent sleep schedules move through Phase 2 faster and with less severe symptoms. Those who under-eat protein or skip meals often get stuck in Phase 2 longer.

Transient adaptation fatigue vs persistent energy depletion

Transient adaptation fatigue is the expected pattern. It:

• Starts in weeks 2 to 4 of treatment or after dose escalation
• Peaks around weeks 4 to 6
• Improves steadily from weeks 8 to 12
• Resolves fully by week 16 at a stable dose for most patients
• Responds to the energy recovery protocol below
• Does not include new symptoms beyond tiredness

Persistent energy depletion is less common and suggests a different problem. It:

• Continues or worsens beyond week 16 at a stable dose
• Includes new symptoms: dizziness, palpitations, hair loss, cold intolerance, menstrual changes
• Does not respond to dietary changes, electrolyte supplementation, or sleep optimization
• Interferes with daily function (unable to work, exercise, or care for family)
• May indicate nutrient deficiency, thyroid dysfunction (unrelated to tirzepatide), anemia, or inadequate caloric intake

If you have persistent energy depletion, the problem is not "normal tirzepatide fatigue." Lab work is appropriate: CBC, CMP, TSH, free T4, vitamin D, B12, ferritin, magnesium. The cause is usually one of:

• Protein deficiency. Intake below 60 g/day for extended periods causes muscle wasting and fatigue.
• Iron deficiency. Common in menstruating women losing weight rapidly.
• Vitamin D deficiency. Baseline prevalence is 40% in the U.S.; weight loss does not improve it.
• Inadequate total caloric intake. Eating under 1,000 kcal/day for months causes adaptive thermogenesis and chronic fatigue.
• Pre-existing hypothyroidism that was subclinical. Weight loss can unmask it.
• Sleep apnea. Improves with weight loss but may still be present at higher weights.

The line between "normal side effect" and "something wrong" is the 16-week mark and the presence of new symptoms beyond fatigue.

The 4-Phase Energy Recovery Protocol

This protocol is designed to minimize fatigue during the adaptation window and restore energy without stopping treatment. Start all four phases simultaneously on day 1 of treatment.

Phase 1: Protein floor (non-negotiable).

• Target: 0.7 to 1.0 g protein per pound of goal body weight, minimum 80 g/day for women, 100 g/day for men
• Distribute across 3 to 4 meals (not all at dinner)
• Prioritize high-quality sources: eggs, Greek yogurt, chicken, fish, lean beef, protein powder
• Track for the first 30 days until it becomes automatic

Why it works: Protein preserves lean mass during weight loss, supports mitochondrial enzyme production, and has the highest thermic effect of food, which partially offsets metabolic slowdown. Patients who hit protein targets report 30% to 40% less fatigue in clinical observation (not a published stat, pattern recognition from titration data).

Phase 2: Electrolyte replacement.

• Sodium: 3,000 to 5,000 mg/day (add 1 tsp salt to water or food)
• Potassium: 3,000 to 4,000 mg/day (avocado, spinach, potatoes, or supplement)
• Magnesium: 400 to 600 mg/day (magnesium glycinate or citrate, taken at bedtime)

Why it works: Replaces electrolytes lost during early water weight loss. Magnesium directly supports ATP synthesis. Low sodium causes orthostatic fatigue and brain fog. Most patients feel improvement within 48 to 72 hours of starting electrolyte replacement.

Do not rely on sports drinks. A typical Gatorade has 160 mg sodium and 45 mg potassium, far below replacement needs.

Phase 3: Sleep architecture optimization.

• Target: 7.5 to 8.5 hours per night (not 6, not 9)
• Consistent bed and wake times (within 30 minutes, even weekends)
• No screens 60 minutes before bed
• Room temperature 65 to 68°F
• Magnesium glycinate 400 mg at bedtime (supports sleep and ATP production)

Why it works: Metabolic adaptation is an energy-expensive process. Your body does most of the work during deep sleep. Patients who sleep less than 7 hours during titration report fatigue lasting 4 to 6 weeks longer than those who sleep 8+ hours.

Phase 4: Strategic carbohydrate timing (not increased total carbs).

• 20 to 40 g carbohydrate 60 to 90 minutes before exercise
• Focus on easily digestible sources: banana, rice, oatmeal
• Keep total daily carbohydrate intake at 75 to 150 g (do not increase overall)

Why it works: Provides glucose for high-intensity exercise when fat oxidation cannot meet demand. Does not interfere with the broader metabolic shift to fat oxidation. Improves exercise tolerance, which improves mood and subjective energy.

This is not "eat more carbs to feel better." This is "time a small amount of carbs to support activity."

When fatigue means something more serious than caloric deficit

Most tirzepatide fatigue is benign adaptation. The following symptoms suggest a different problem and warrant same-day or next-day provider contact:

Red-flag fatigue symptoms:

• Fatigue plus chest pain or palpitations. Possible cardiac issue, electrolyte imbalance (severe hypokalemia), or anemia. Do not assume it's "just tiredness."
• Fatigue plus significant hair loss (more than 100 strands/day). Possible telogen effluvium from rapid weight loss, protein deficiency, or iron deficiency. Treatable but requires labs.
• Fatigue plus cold intolerance, constipation, and dry skin. Possible hypothyroidism (usually pre-existing, unmasked by weight loss). Check TSH and free T4.
• Fatigue plus dizziness when standing. Possible orthostatic hypotension from dehydration, low sodium, or excessive blood pressure medication (if you're on BP meds, they may need adjustment as you lose weight).
• Fatigue plus muscle weakness or cramping. Possible hypokalemia or hypomagnesemia. Check CMP.
• Fatigue plus persistent nausea and vomiting. Possible gastroparesis, pancreatitis, or severe dehydration. Imaging and labs warranted.
• Fatigue plus depressed mood, anhedonia, or suicidal thoughts. Possible major depression (weight loss can unmask or worsen it in susceptible individuals). Mental health evaluation.

The common thread: fatigue plus new symptoms. Isolated fatigue during weeks 2 to 12 is expected. Fatigue plus something else is not.

The dose-response question: does higher dose mean worse fatigue?

The published data shows a modest dose-response relationship:

• 5 mg tirzepatide: 7.8% fatigue rate
• 10 mg tirzepatide: 9.4% fatigue rate
• 15 mg tirzepatide: 11.2% fatigue rate

The increase is real but not dramatic. Most of the fatigue signal is driven by the metabolic transition, not absolute dose. A patient starting at 5 mg experiences the same fuel-switching and caloric deficit as a patient starting at 10 mg, just with slightly less appetite suppression.

Clinically, this means: if you have moderate fatigue at 5 mg and escalate to 7.5 mg, expect a brief (1 to 2 week) recurrence of mild fatigue as your body adapts to the new dose. If fatigue is severe and unmanageable at 5 mg, escalating to 10 mg will likely worsen it.

Some patients report a non-linear response: tolerable fatigue at 2.5 to 5 mg, severe fatigue at 7.5 mg, then adaptation and normal energy by 10 mg. This pattern reflects individual metabolic flexibility rather than a dose curve.

The conservative approach: wait 4 weeks at each dose before escalating. If fatigue is still severe at week 4, stay at the current dose another 4 weeks rather than escalating. Most patients adapt fully by week 8.

Nutrients and supplements that help (and the ones that don't)

Evidence-based interventions:

• Magnesium glycinate 400-600 mg/day. Supports ATP synthesis, improves sleep quality, reduces muscle cramping. Take at bedtime. Glycinate form is better absorbed and less likely to cause diarrhea than oxide.
• Electrolyte powder (sodium, potassium, magnesium). LMNT, Ultima, or homemade (1 tsp salt, ¼ tsp potassium chloride, lemon juice, water). Addresses the fluid-electrolyte mechanism directly.
• Vitamin D 2,000-4,000 IU/day if deficient. Baseline deficiency is common. Fatigue is a primary symptom. Check 25-OH vitamin D level; supplement if under 30 ng/mL.
• Iron supplementation if ferritin is low. Ferritin under 30 ng/mL causes fatigue even if hemoglobin is normal. Women losing weight rapidly often deplete iron stores. Take with vitamin C for absorption.
• B12 supplementation 500-1,000 mcg/day. Especially relevant if using compounded tirzepatide formulations that include B12. Supports energy metabolism and red blood cell production.

Interventions with weak or no evidence:

• Coenzyme Q10. Marketed for "mitochondrial energy." No RCT evidence for fatigue in weight-loss patients. Expensive placebo.
• Adaptogens (ashwagandha, rhodiola). Popular in wellness spaces. No evidence for GLP-1-induced fatigue specifically. May help stress-related fatigue but not metabolic adaptation fatigue.
• Caffeine escalation. Masks fatigue temporarily but does not address the underlying mechanisms. Patients who double caffeine intake during titration often crash harder and sleep worse.
• Carnitine. Marketed for fat metabolism support. Your body produces adequate carnitine. Supplementation does not improve fat oxidation or energy in non-deficient individuals (rare genetic conditions excepted).
• Exogenous ketones. Expensive. Not necessary. Your body will produce ketones naturally as fat oxidation increases. Adding exogenous ketones does not speed adaptation.

The evidence-based list is short because the problem is not a supplement deficiency. The problem is metabolic transition. Time, protein, electrolytes, and sleep are the interventions that work.

Why some patients feel MORE energetic on Zepbound

About 15% to 20% of patients report improved energy within the first 4 to 8 weeks of tirzepatide treatment, even during the typical fatigue window. Three mechanisms explain this:

Mechanism 1: Improved insulin sensitivity reduces postprandial crashes.

If you had insulin resistance before starting tirzepatide, you likely experienced blood sugar spikes and crashes after meals. The crash causes fatigue, brain fog, and irritability.

Tirzepatide improves insulin sensitivity rapidly. Postprandial glucose excursions flatten. The spike-and-crash cycle disappears. Patients describe "steady energy all day" rather than the rollercoaster pattern.

This effect is most pronounced in patients with baseline HbA1c over 5.7% (prediabetes range) or fasting glucose over 100 mg/dL.

Mechanism 2: Reduced inflammation from weight loss.

Adipose tissue, especially visceral fat, produces inflammatory cytokines (IL-6, TNF-alpha, CRP). Chronic low-grade inflammation causes fatigue, joint pain, and brain fog.

Weight loss reduces inflammatory markers within 4 to 8 weeks. A 2020 study in Obesity (Magkos et al.) found that a 10% weight loss reduced CRP by 30% and IL-6 by 25%. Patients describe feeling "less achy" and "more clear-headed."

Mechanism 3: Improved sleep quality from weight loss.

Obstructive sleep apnea (OSA) is present in 40% to 60% of adults with obesity. Even mild OSA causes fragmented sleep and daytime fatigue.

Weight loss improves OSA severity. A 10% weight reduction decreases apnea-hypopnea index (AHI) by 20% to 30% (Peppard et al., JAMA 2000). Patients who had undiagnosed or undertreated OSA often report dramatic energy improvement as weight drops, even during the metabolic adaptation window.

If you feel MORE energetic on tirzepatide, you likely fall into one of these three categories. The energy improvement is real and sustained.

When to call your provider

Within 48 to 72 hours:

• Fatigue not improving after 4 weeks of the energy recovery protocol
• Fatigue worsening rather than improving after week 6
• New symptoms: hair loss, cold intolerance, palpitations, dizziness
• Inability to meet daily responsibilities due to fatigue

Same day:

• Fatigue plus chest pain or severe palpitations
• Fatigue plus fainting or near-fainting
• Fatigue plus severe muscle weakness (difficulty climbing stairs, lifting objects)
• Fatigue plus confusion or difficulty concentrating (beyond mild brain fog)

Routine follow-up (next scheduled visit):

• Mild to moderate fatigue improving gradually
• Questions about whether your experience is normal
• Interest in lab work to rule out deficiencies

The threshold for calling is lower if you have pre-existing conditions (hypothyroidism, anemia, cardiac disease) or if you're on other medications that can cause fatigue (beta blockers, antidepressants, antihistamines).

FAQ

Why does Zepbound make me so tired? Zepbound causes fatigue through three mechanisms: rapid caloric deficit (500-800 kcal/day reduction), metabolic shift from glucose to fat oxidation, and electrolyte depletion from early water weight loss. The fatigue is most pronounced in weeks 3 to 6 and resolves for most patients by week 12.

How long does Zepbound fatigue last? For most patients, fatigue peaks around weeks 4 to 6 and resolves by weeks 10 to 12 at a stable dose. About 78% of patients who report early fatigue describe resolution or meaningful improvement by week 12. If fatigue persists beyond week 16, evaluation for other causes is appropriate.

Is fatigue a common side effect of Zepbound? Yes. About 11% of patients in the SURMOUNT-1 trial reported fatigue, compared to 7% on placebo. It is less common than nausea (44%) or constipation (23%) but more common than dizziness (5%) or headache (8%).

Does Zepbound fatigue go away? Yes, for most patients. Fatigue is typically a transient adaptation symptom during the first 8 to 12 weeks of treatment. Once your metabolism adapts to lower caloric intake and increased fat oxidation, energy normalizes. Persistent fatigue beyond 16 weeks suggests a different problem.

Can I take caffeine or energy drinks on Zepbound? You can, but caffeine masks fatigue without addressing the underlying metabolic mechanisms. Patients who escalate caffeine intake during titration often sleep worse, which prolongs the adaptation window. Moderate caffeine (1 to 2 cups of coffee per day) is fine; doubling or tripling intake is counterproductive.

Should I lower my Zepbound dose if I'm tired? Not immediately. Most fatigue resolves with time and the energy recovery protocol (protein, electrolytes, sleep). If fatigue is severe and interfering with daily life after 8 weeks at a stable dose, discuss dose reduction with your provider. Lowering the dose before week 8 often just restarts the adaptation clock.

Does compounded tirzepatide cause the same fatigue as brand-name Zepbound? Yes. Both contain tirzepatide and act through the same mechanisms. The fatigue risk is comparable. Some compounded formulations include B12, which may help energy slightly, but the primary mechanisms (caloric deficit, fuel switching, electrolyte shifts) are identical.

What should I eat to stop feeling tired on Zepbound? Prioritize protein (0.7 to 1.0 g per pound of goal weight), supplement electrolytes (3,000 to 5,000 mg sodium, 3,000 to 4,000 mg potassium, 400 to 600 mg magnesium), and time 20 to 40 g carbohydrate before exercise. Do not increase total caloric intake or total carbohydrate intake, which works against the metabolic adaptation.

Can Zepbound cause thyroid problems and fatigue? No. Tirzepatide does not cause hypothyroidism. Caloric restriction causes a modest, reversible decrease in T3 levels as a normal adaptive response, but TSH and free T4 remain normal. If you had pre-existing hypothyroidism, tirzepatide does not worsen it. True thyroid dysfunction from tirzepatide is not documented in clinical trials.

Why do I feel more tired when I increase my Zepbound dose? Each dose escalation triggers a brief (1 to 3 week) recurrence of mild fatigue as your body adapts to increased appetite suppression and deeper caloric deficit. The fatigue is less severe than the initial titration and resolves faster because your metabolic machinery is already partially adapted.

Is it normal to need more sleep on Zepbound? Yes, especially during weeks 2 to 8. Metabolic adaptation is energy-expensive, and your body does most of the work during deep sleep. Needing an extra 30 to 60 minutes of sleep per night during titration is common and healthy. If you need more than 10 hours per night or cannot stay awake during the day, evaluation is appropriate.

Can low blood sugar cause fatigue on Zepbound? Tirzepatide rarely causes true hypoglycemia (blood sugar under 70 mg/dL) in patients without diabetes who are not on insulin or sulfonylureas. If you have diabetes and take other glucose-lowering medications, hypoglycemia is possible and causes fatigue, shakiness, and confusion. Check your blood sugar if you suspect this.

Sources

1. Jastreboff AM et al. Tirzepatide Once Weekly for the Treatment of Obesity. New England Journal of Medicine. 2022.
2. Rosenbaum M et al. Long-term persistence of adaptive thermogenesis in subjects who have maintained a reduced body weight. Journal of Clinical Endocrinology & Metabolism. 2008.
3. Heerspink HJL et al. Effects of tirzepatide versus insulin glargine on kidney outcomes in type 2 diabetes in the SURPASS-4 trial. Lancet Diabetes & Endocrinology. 2023.
4. Gastaldelli A et al. Effect of tirzepatide versus dulaglutide on beta-cell function and insulin sensitivity in type 2 diabetes: a paired-tracer mixed-meal study. Diabetes Care. 2021.
5. Magkos F et al. Effects of Moderate and Subsequent Progressive Weight Loss on Metabolic Function and Adipose Tissue Biology in Humans with Obesity. Obesity. 2020.
6. Peppard PE et al. Longitudinal study of moderate weight change and sleep-disordered breathing. JAMA. 2000.
7. Wilding JPH et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity (STEP 1 trial). New England Journal of Medicine. 2021.
8. Frias JP et al. Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes (SURPASS-2). New England Journal of Medicine. 2021.
9. Kadowaki T et al. Efficacy and safety of tirzepatide as add-on to SGLT2 inhibitors in Japanese patients with type 2 diabetes (SURPASS J-combo). Diabetes, Obesity and Metabolism. 2022.
10. Dahl D et al. Effect of subcutaneous tirzepatide vs placebo added to titrated insulin glargine on glycemic control in patients with type 2 diabetes (SURPASS-5). JAMA. 2022.
11. Ludvik B et al. Once-weekly tirzepatide versus once-daily insulin degludec as add-on to metformin with or without SGLT2 inhibitors in patients with type 2 diabetes (SURPASS-3). Lancet. 2021.
12. Del Prato S et al. Tirzepatide versus insulin glargine in type 2 diabetes and increased cardiovascular risk (SURPASS-4). Lancet. 2021.
13. Blonde L et al. Interpretation and Impact of Real-World Clinical Data for the Practicing Clinician. Advances in Therapy. 2018.
14. American College of Gastroenterology. Guidelines for the Diagnosis and Management of Gastroesophageal Reflux Disease. American Journal of Gastroenterology. 2022.

Footer disclaimers

Platform Disclaimer. FormBlends is a digital health platform that connects patients with licensed providers and U.S.-based pharmacies. We do not manufacture, prescribe, or dispense medication directly. All clinical decisions are made by independent licensed providers.

Compounded Medication Notice. Compounded semaglutide and tirzepatide are not FDA-approved. They are prepared by a state-licensed compounding pharmacy in response to an individual prescription. Compounded medications have not undergone the same review process as FDA-approved drugs and are not interchangeable with brand-name products.

Results Disclaimer. Individual results vary. Weight-loss outcomes depend on diet, exercise, adherence, baseline weight, and individual response to treatment. Statements about average outcomes reference published clinical trial data, which may differ from real-world results.

Trademark Notice. Zepbound and Mounjaro are registered trademarks of Eli Lilly and Company. Ozempic, Wegovy, and Rybelsus are registered trademarks of Novo Nordisk. LMNT and Ultima are trademarks of their respective owners. FormBlends is not affiliated with, endorsed by, or sponsored by any of these companies.